4D Molecular Therapeutics (FDMT) Leases (2021 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Leases for 5 consecutive years, with $18.9 million as the latest value for Q3 2025.
- On a quarterly basis, Leases fell 13.12% to $18.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.9 million, a 13.12% decrease, with the full-year FY2024 number at $21.1 million, up 82.63% from a year prior.
- Leases was $18.9 million for Q3 2025 at 4D Molecular Therapeutics, down from $19.6 million in the prior quarter.
- In the past five years, Leases ranged from a high of $21.8 million in Q3 2024 to a low of $10.7 million in Q2 2024.
- A 5-year average of $15.1 million and a median of $13.6 million in 2022 define the central range for Leases.
- Peak YoY movement for Leases: fell 13.47% in 2024, then surged 83.84% in 2025.
- 4D Molecular Therapeutics' Leases stood at $14.6 million in 2021, then dropped by 10.14% to $13.1 million in 2022, then decreased by 11.82% to $11.5 million in 2023, then surged by 82.63% to $21.1 million in 2024, then decreased by 10.28% to $18.9 million in 2025.
- Per Business Quant, the three most recent readings for FDMT's Leases are $18.9 million (Q3 2025), $19.6 million (Q2 2025), and $20.4 million (Q1 2025).